Water Tower Research Highlights Ainos' Transition to Technology Company Following GICS Reclassification
Ainos (NASDAQ:AIMD) was reclassified under GICS from biotechnology to the technology sector effective October 1, 2025, reflecting its shift to an AI-powered digital olfaction platform, AI Nose.
Water Tower Research highlighted commercial milestones: first revenue of $110,000 from a 1H 2025 elderly care pilot, a three-year SmellTech-as-a-Service order worth $2.1 million for semiconductor manufacturing, seven Japan pilots with a robotic partner, five new industry partners, and an expanded IP portfolio now at 123 active patents and applications including seven recent patents across Europe, Germany, Taiwan, and China. Large-scale commercialization is scheduled for 2026.
Ainos (NASDAQ:AIMD) è stato riclassificato secondo GICS dallo settore biotecnologico a quello tecnologico con effetto dal 1 ottobre 2025, riflettendo il passaggio a una piattaforma di olfazione digitale basata su IA, AI Nose.
Water Tower Research ha evidenziato traguardi commerciali: il primo fatturato di $110,000 proveniente da un pilota di assistenza agli anziani nella prima metà del 2025, un ordine SmellTech-as-a-Service di tre anni del valore di 2,1 milioni di dollari per la produzione di semiconduttori, 123 brevetti e domande attivi ora nell'IP portfolio ampliato, inclusi sette brevetti recenti in Europa, Germania, Taiwan e Cina. sette piloti in Giappone con un partner robotico, cinque nuovi partner di settore, e una espansione dell’IP portfolio ora a 123 brevetti e domande attivi inclusi sette brevetti recenti in Europa, Germania, Taiwan e Cina. La commercializzazione su larga scala è prevista per 2026.
Ainos (NASDAQ:AIMD) fue reclasificado bajo GICS desde biotecnología al sector tecnológico, con efecto a partir del 1 de octubre de 2025, reflejando su transición a una plataforma de olfacción digital impulsada por IA, AI Nose.
Water Tower Research destacó hitos comerciales: los primeros ingresos de $110,000 provenientes de un piloto de cuidado de personas mayores en la primera mitad de 2025, un pedido de SmellTech-as-a-Service de tres años por 2,1 millones de dólares para la fabricación de semiconductores, 123 patentes y solicitudes activas en un portafolio de IP ampliado, incluidos siete patentes recientes en Europa, Alemania, Taiwán y China. Siete pilotos en Japón con un socio robótico, cinco nuevos socios industriales, y una expansión del portafolio de IP se planea para una comercialización a gran escala en 2026.
Ainos (NASDAQ:AIMD)는 GICS에 따라 생명공학에서 기술 섹터로 2025년 10월 1일부로 재분류되었으며 이는 AI 기반 디지털 후각 플랫폼인 AI Nose로의 전환을 반영합니다.
Water Tower Research는 상용화 이정표를 강조했습니다: 2025년 상반기에 elderly care 파일럿으로부터 $110,000의 첫 매출, 반도체 제조를 위한 3년 SmellTech-as-a-Service 주문 210만 달러, 로봇 파트너와 함께하는 일본의 파일럿 7건, 5개의 신규 산업 파트너, 그리고 확장된 IP 포트폴리오가 이제 123 활발한 특허 및 출원으로 포함되며 유럽, 독일, 대만, 중국에서 최근 특허 7건을 포함합니다. 대규모 상용화는 2026년으로 예정되어 있습니다.
Ainos (NASDAQ:AIMD) a été reclassé selon le GICS du biotechnologique vers le secteur technologique avec effet au 1 octobre 2025, reflétant son passage à une plateforme d’olfaction numérique alimentée par l’IA, AI Nose.
Water Tower Research a mis en évidence des jalons commerciaux: un premier chiffre d’affaires de $110,000 provenant d’un pilote de soins aux personnes âgées au premier semestre 2025, une commande de SmellTech-as-a-Service sur trois ans d’une valeur de 2,1 millions de dollars pour la fabrication de semi-conducteurs, 123 brevets et demandes actifs dans un portefeuille IP élargi, y compris sept brevets récents en Europe, en Allemagne, à Taïwan et en Chine. sept pilotes au Japon avec un partenaire robotique, cinq nouveaux partenaires industriels, et une extension du portefeuille IP est prévue pour une commercialisation à grande échelle en 2026.
Ainos (NASDAQ:AIMD) wurde gemäß GICS vom Biotechnologie-Sektor in den Technologie-Sektor mit Wirkung zum 1. Oktober 2025 umklassifiziert, was die Verschiebung zu einer KI-gestützten digitalen Geruchsfunktion-Plattform AI Nose widerspiegelt.
Water Tower Research hob kommerzielle Meilensteine hervor: erster Umsatz von $110,000 aus einem Pilotprojekt zur Altenpflege in der ersten Hälfte von 2025, eine drei-Jahres-SmellTech-as-a-Service-Bestellung im Wert von 2,1 Mio. $ für die Halbleiterfertigung, 123 Patente und Anmeldungen aktiv, einschließlich sieben kürzlich erteilten Patenten in Europa, Deutschland, Taiwan und China. Sieben Piloten in Japan mit einem Roboterpartner, fünf neue Industriepartner und eine erweiterte IP-Portfolios, geplant für eine groß angelegte Kommerzialisierung im 2026.
Ainos (NASDAQ:AIMD) تم إعادة تصنيفها وفقاً لـGICS من قطاع التكنولوجيا الحيوية إلى قطاع التكنولوجيا ساري المفعول اعتباراً من 1 أكتوبر 2025، وهو ما يعكس انتقالها إلى منصة شم صناعي رقمية مدعومة بالذكاء الاصطناعي، AI Nose.
سلطت Water Tower Research الضوء على معالم تجارية: الإيراد الأول بنحو $110,000 من تجربة رعاية كبار السن في النصف الأول من 2025، طلب SmellTech-as-a-Service لمدة ثلاث سنوات بقيمة 2.1 مليون دولار لصناعة أشباه الموصلات، سبعة تجارب في اليابان مع شريك روبوتي، خمسة شركاء صناعيين جدد، ووسع لمحفظة الملكية الفكرية الآن إلى 123 براءة اختراع وتقديمات نشطة بما في ذلك سبعة براءات حديثة في أوروبا وألمانيا وتايوان والصين. من المقرر تحويلها إلى سوق واسع النطاق في 2026.
Ainos (NASDAQ:AIMD) 已根据 GICS 自 2025 年 10 月 1 日起从生物技术板块重新分类至 技术板块，反映其转向由 AI 驱动的数字嗅觉平台 AI Nose。
Water Tower Research 强调了商业里程碑：来自 2025 年上半年老年护理试点的首次收入 $110,000，一个三年期的 SmellTech-as-a-Service 订单，价值 210 万美元，用于半导体制造，七个日本试点与机器人合作伙伴，五个新的行业伙伴，以及扩大的 IP 组合现已达到 123 项活跃专利与申请，其中包括在欧洲、德国、台湾和中国的七项近期专利。计划于 2026 实现大规模商业化。
- GICS reclassification to technology effective Oct 1, 2025
- First revenue of $110,000 from 1H 2025 elderly care pilot
- Signed a 3-year SmellTech-as-a-Service order valued at $2.1M
- Expanded IP to 123 active patents and applications
- Added 5 industry partners and launched 7 pilots with a robotic partner
- Initial commercial revenue remains small at $110,000
- Large-scale commercialization is not scheduled until 2026, delaying broader revenue visibility
Insights
GICS reclassification and early commercial wins increase visibility and validate a nascent SmellTech-as-a-Service revenue model.
The GICS move to technology aligns benchmarking and index inclusion with tech peers and can widen investor attention toward recurring revenue and platform metrics. The company reports initial commercial validation with
Key dependencies and risks remain clear: large‑scale commercialization is slated for
Watch the 2026 commercialization rollout, incremental contract announcements, and quarter‑over‑quarter revenue and recurring contract metrics over the next 12–18 months to gauge commercial traction and index eligibility impact.
New GICS code increases visibility among technology investors as Ainos builds commercial momentum around its AI-powered digital olfaction platform
Expanded partnerships and IP portfolio to strengthen Ainos' SmellTech-as-a-Service model and competitive edge
SAN DIEGO, CALIFORNIA / ACCESS Newswire / October 7, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-powered scent digitization, today announced that Water Tower Research (WTR) issued a new report spotlighting Ainos' formal reclassification under the Global Industry Classification Standard (GICS®) to the technology sector from biotechnology, effective October 1, 2025. The report recognizes Ainos' transformation into a technology-driven company built around its proprietary AI-powered digital olfaction platform, AI Nose.
Key Highlights from the Report
GICS reclassification signals key strategic evolution: The transition underscores Ainos' increasing commercial momentum on AI-powered sensing and digital olfaction powered by AI Nose and smell language model (SLM). Given this strategic pivot, WTR assumed coverage of Ainos under its technology research platform in August.
Greater visibility among technology-focused investors: With the GICS update,Ainos will now be benchmarked alongside global technology peers and can be included in indices that focus on tech stocks. This move expands Ainos' visibility among technology-oriented investors, funds, and ETFs, shifting market attention toward AI Nose's recurring revenue potential and user adoption metrics as Ainos advances its SmellTech-as-a-Service model.
AI Nose gains commercial traction through broader partnership ecosystem: Ainos generated its first revenue of
$110,000 from an elderly care pilot program during 1H 2025, with additional tractions accelerating in 2H 2025 ahead of large-scale commercialization scheduled for 2026. The Company also secured its first three-year SmellTech-as-a-Service order valued at$2.1 million for semiconductor manufacturing, marking its first long-term commercial win. In Japan, seven pilots are being launched with its first robotic partner, marking Ainos' growing footprint in the robotics market. Overall, Ainos has expanded its industrial ecosystem this year by adding five partners across semiconductors, robotics, and smart manufacturing.
Expanding IP portfolio strengthens competitive moat: The Company recently secured seven new patents across Europe, Germany, Taiwan, and China, reinforcing its leadership in AI-powered olfaction technologies and their applications in robotics. Ainos now holds 123 active patents and applications across its key technologies spanning the U.S., Europe, Germany, Japan, Taiwan, and China.
Read the Full Water Tower Research Report Here: https://www.watertowerresearch.com/doc?docID=UR_AIMD_10032025
"Our GICS reclassification reflects more than just a new industry code-it marks a company-wide transformation," said Eddy Tsai, Chairman, President and CEO of Ainos. "We've realigned our internal R&D to strengthen this direction by establishing a new Smart Healthcare Sensing division to advance AI Nose's healthcare applications, and by forming a subsidiary dedicated to developing our AI platform, the smell language model (SLM). These initiatives position Ainos to lead the next frontier of sensory intelligence and unlock new value across healthcare, industrial, and robotic ecosystems."
About Ainos, Inc.
Ainos, Inc. (NASDAQ:AIMD) is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X, formerly known as Twitter, (@AinosInc) and LinkedIn to stay up-to-date.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What did Ainos (AIMD) announce about its GICS classification on October 1, 2025?
How much revenue did Ainos (AIMD) generate from its first pilot in 1H 2025?
What is the value and term of Ainos' first long-term commercial order?
How many patents does Ainos (AIMD) hold after the recent additions?
When is Ainos planning large-scale commercialization of AI Nose?
Will the GICS change affect Ainos' investor visibility for AIMD?
